Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Results clearly exceeded expectations, with a substantial revenue beat leading to smaller losses in what looks like a definite win for investors. Revenues were US$2.4m and the statutory loss per share was US$0.24, smaller than the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Aclaris Therapeutics, Inc.(納斯達克股票代碼:ACRS)無視分析師的預期,公佈了第一季度業績,該業績超出了市場預期。業績顯然超出了預期,可觀的收入超過預期,從而減少了損失,這對投資者來說無疑是勝利。收入爲240萬美元,每股法定虧損爲0.24美元,低於分析師的預期。對於投資者來說,這是一個重要時刻,因爲他們可以在報告中追蹤公司的業績,看看專家對明年的預測,看看對該業務的預期是否有任何變化。因此,我們收集了最新的業績後法定共識估計,以了解明年可能會發生什麼。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240510/0-a6ae46bd180c1fa31b47c0b98188f9d0-0-6e2bea9313b1668bad7c949d818db503.png/big)
Following the recent earnings report, the consensus from seven analysts covering Aclaris Therapeutics is for revenues of US$8.50m in 2024. This implies a sizeable 73% decline in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 31% to US$0.75. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$7.76m and losses of US$0.97 per share in 2024. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a very favorable reduction to loss per share in particular.
繼最近的業績發佈之後,七位報道Aclaris Therapeutics的分析師一致認爲,2024年的收入爲850萬美元。這意味着與過去12個月相比,收入大幅下降了73%。預計損失將大幅下降,萎縮31%,至0.75美元。然而,在最新業績公佈之前,分析師一直預測2024年收入爲776萬美元,每股虧損0.97美元。市場情緒明顯增強,分析師增加了收入,尤其是每股虧損的降幅非常有利。
Despite these upgrades,the analysts have not made any major changes to their price target of US$1.84, implying that their latest estimates don't have a long term impact on what they think the stock is worth. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Aclaris Therapeutics at US$3.00 per share, while the most bearish prices it at US$1.00. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
儘管進行了這些上調,但分析師並未對1.84美元的目標股價做出任何重大調整,這意味着他們的最新估計不會對他們認爲該股的價值產生長期影響。但是,固定單一價格目標可能是不明智的,因爲共識目標實際上是分析師目標股價的平均值。因此,一些投資者喜歡查看估計範圍,看看對公司的估值是否有任何分歧。目前,最看漲的分析師對Aclaris Therapeutics的估值爲每股3.00美元,而最看跌的分析師估值爲每股1.00美元。在這種情況下,我們可能會減少對分析師預測的估值,因爲如此廣泛的估計可能意味着該業務的未來難以準確估值。因此,根據共識目標股價做出決策可能不是一個好主意,畢竟共識目標價只是如此廣泛的估計值的平均值。
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 82% by the end of 2024. This indicates a significant reduction from annual growth of 45% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 9.4% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Aclaris Therapeutics is expected to lag the wider industry.
了解這些預測的更多背景信息的一種方法是研究它們與過去的業績相比如何,以及同一行業中其他公司的表現。這些估計表明,收入預計將放緩,預計到2024年底年化下降82%。這表明與過去五年45%的年增長率相比大幅下降。相比之下,我們的數據表明,在可預見的將來,預計同一行業的其他公司(有分析師報道)的收入每年將增長9.4%。因此,儘管預計其收入將萎縮,但這種雲並沒有帶來一線希望——預計Aclaris Therapeutics將落後於整個行業。
The Bottom Line
底線
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. The consensus price target held steady at US$1.84, with the latest estimates not enough to have an impact on their price targets.
最明顯的結論是,分析師對明年虧損的預測沒有改變。他們還上調了明年的收入預期,儘管預計其增長速度將低於整個行業。共識目標股價穩定在1.84美元,最新估計不足以對其目標價格產生影響。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Aclaris Therapeutics analysts - going out to 2026, and you can see them free on our platform here.
話雖如此,公司收益的長期軌跡比明年重要得多。根據多位Aclaris Therapeutics分析師的估計,到2026年,你可以在我們的平台上免費查看。
Plus, you should also learn about the 3 warning signs we've spotted with Aclaris Therapeutics (including 1 which is a bit unpleasant) .
另外,你還應該了解我們在Aclaris Therapeutics中發現的3個警告信號(包括一個有點不愉快的警告信號)。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。